NCT07943039
Safety and Efficacy of pALG in Conditioning Regimen for HLA-Matched Sibling HSCT in Patients With SAA or Hematological Malignancies ( pALG-MSDHSCT )
StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Incidence of acute graft-versus-host disease (aGVHD)
Timeframe: within 100 days after hematopoietic stem cell infusion
Incidence of chronic graft-versus-host disease (cGVHD)
Timeframe: 5 years after hematopoietic stem cell transplantation
Secondary (8)
1-year implantation rate
Overall survival rate
Rejection (AA) or recurrence (malignant)
Incidence of fungal infection
Incidence of cytomegalovirus infection
Show 3 moreShow less
Incidence of Epstein-Barr virus infection
Transplant-related mortality
Drug-related toxic and side effects from hematopoietic stem cell infusion to the last
Arms and interventions
p-ALG cohort
(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days.
Drugs: Exploration of porcine anti-human T-lymphocyte immunoglobulin (p-ALG)
Sites
1 site in 1 country
- National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College HospitalTianjin, Tianjin Municipality, China